蒋 怡,沙仁高娃

子宫内膜异位症（endometriosis,EMs）是指子宫内膜腺体和间质出现在子宫体以外的部位，简称内异症，其中卵巢子宫内膜异位囊肿是最常见的病理类型。EMs是一种雌激素依赖性全身慢性炎症性疾病，主要表现为慢性盆腔疼痛、痛经、不孕等，目前EMs的病因及发病机制尚不清楚。EMs的治疗包括手术治疗和药物治疗，其中手术治疗是最基本的治疗，由于该疾病的复发率高，需要进行长期管理，长期管理的关键是药物治疗，常用的药物包括口服避孕药、孕激素类、中医中药、促性腺激素释放激素激动剂等，随着对该疾病的不断深入研究，更多新药用于该疾病的治疗，如促性腺激素释放激素拮抗剂（Elagolix、Relugolix），本文就促性腺激素释放激素激动剂在卵巢子宫内膜异位囊肿的治疗展开综述。

子宫内膜异位囊肿；促性腺激素释放激素激动剂；卵巢功能

[1] Montgomery G W,Giudice L C.New lessons about endometriosis-somatic mutations and disease heterogeneity[J].New England Journal of Medicine,2017,376(19):1881-1882. [2] Czyzyk A,Podfigurna A,Szeliga A,et al.Update on endometriosis pathogenesis[J].Minerva Ginecologica,2017,69(5):447-461. [3] Vercellini P,ViganòP,Somigliana E,et al.Endometriosis:pathogenesis and treatment[J].Nature Reviews Endocrinology,2014,10(5):261-275. [4] Bonavina G,Taylor H S.Endometriosis-associated infertility:From pathophysiology to tailored treatment[J].Frontiers in endocrinology,2022,13:1020827. [5] 中国医师协会妇产科医师分会,中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症诊治指南(第三版)[J].中华妇产科杂志,2021,56(12):812-824. [6] 郎景和.对子宫内膜异位症认识的历史､现状与发展[J].中国实用妇科与产科杂志,2020,36(03):193-196. [7] Raffi F,Metwally M,Amer S.The impact of excision of ovarian endometrioma on ovarian reserve:a systematic review and meta-analysis[J].The Journal of Clinical Endocrinology&Metabolism,2012,97(9):3146-3154. [8] Younis J S,Shapso N,Fleming R,et al.Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve:a systematic review and meta-analysis[J].Human reproduction update,2018,25(3):375-391. [9] Zhang Y,Zhang S,Zhao Z,et al.Impact of cystectomy versus ablation for endometrioma on ovarian reserve:a systematic review and meta-analysis[J].Fertility and sterility,2022,118(6):1172-1182. [10] Kasapoglu I,Ata B,Uyaniklar O,et al.Endometrioma-related reduction in ovarian reserve(ERROR):a prospective longitudinal study[J].Fertility and sterility,2018,110(1):122-127. [11] KaradağC,Yoldemir T,Demircan KaradağS,et al.The effects of endometrioma size and bilaterality on ovarian reserve[J].Journal of Obstetrics and Gynaecology,2020,40(4):531-536. [12] Hwu Y M,Wu F S Y,Li S H,et al.The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels[J].Reproductive Biology and Endocrinology,2011,9:1-8. [13] Santulli P,Marcellin L,Tosti C,et al.MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?[J].Expert opinion on therapeutic targets,2015. [14] Graziottin A.The shorter,the better:A review of the evidence for a shorter contraceptive hormone-free interval[J].The European Journal of Contraception&Reproductive Health Care,2016,21(2):93-105. [15] Laux-Biehlmann A,d’Hooghe T,Zollner T M.Menstruation pulls the trigger for inflammation and pain in endometriosis[J].Trends in pharmacological sciences,2015,36(5):270-276. [16] Reis F M,Petraglia F,Taylor R N.Endometriosis:hormone regulation and clinical consequences of chemotaxis and apoptosis[J].Human reproduction update,2013,19(4):406-418. [17] Vercellini P,Crosignani P,Somigliana E,et al.The‘incessant menstruation’hypothesis:a mechanistic ovarian cancer model with implications for prevention[J].Human reproduction,2011,26(9):2262-2273. [18] Vercellini P,De Giorgi O,Aimi G,et al.Menstrual characteristics in women with and without endometriosis[J].Obstetrics&Gynecology,1997,90(2):264-268. [19] Donnez J,Taylor R N,Taylor H S.Partial suppression of estradiol:a new strategy in endometriosis management?[J].Fertility and sterility,2017,107(3):568-570. [20] Harada T,Kosaka S,Elliesen J,et al.Ethinylestradiol 20μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain:a randomized controlled trial[J].Fertility and Sterility,2017,108(5):798-805. [21] LidegaardØ,Nielsen L H,Skovlund C W,et al.Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses:Danish cohort study,2001-9[J]. Bmj,2011,343. [22] Horne A,Critchley H O D.Medical therapies:progestins[J].Endometriosis:Science and Practice,2011:351-356. [23] Vercellini P,Pietropaolo G,De Giorgi O,et al.Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate[J].Fertility and sterility,2005,84(5):1375-1387. [24] Bergqvist A,Theorell T.Changes in quality of life after hormonal treatment of endometriosis[J].Acta Obstetricia et Gynecologica Scandinavica,2001,80(7):628-637. [25] Harrison R F,Barry-Kinsella C.Efficacy of medroxyprogesterone treatment in infertile women with endometriosis:a prospective,Randomized,placebo-controlled study[J].Fertility and sterility,2000,74(1):24-30. [26] Vercellini P,De Giorgi O,Mosconi P,et al.Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis[J].Fertility and sterility,2002,77(1):52-61. [27] Cosson M,Querleu D,Donnez J,et al.Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery:results of a prospective,multicenter,randomized study[J].Fertility and sterility,2002,77(4):684-692. [28] Strowitzki T,Marr J,Gerlinger C,et al.Detailed analysis of a randomized,multicenter,comparative trial of dienogest versus leuprolide acetate in endometriosis[J].International Journal of Gynecology&Obstetrics,2012,117(3):228-233. [29] Petraglia F,Hornung D,Seitz C,et al.Reduced pelvic pain in women with endometriosis:efficacy of long-term dienogest treatment[J].Archives of gynecology and obstetrics,2012,285:167-173. [30] Crosignani P G,Luciano A,Ray A,et al.Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain[J].Human Reproduction,2006,21(1):248-256. [31] Walch K,Unfried G,Huber J,et al.Implanon versus medroxyprogesterone acetate:effects on pain scores in patients with symptomatic endometriosis—a pilot study[J].Contraception,2009,79(1):29-34. [32] Vercellini P,ViganòP,Somigliana E.The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis[J].Current Opinion in Obstetrics and Gynecology,2005,17(4):359-365. [33] Vercellini P,Somigliana E,Consonni D,et al.Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia:I.Effect on pain during intercourse and patient satisfaction[J].Human reproduction,2012,27(12):3450-3459. [34] Chwalisz K,Surrey E,Stanczyk F Z.The hormonal profile of norethindrone acetate:rationale for add-back therapy with gonadotropinreleasing hormone agonists in women with endometriosis[J].Reproductive Sciences,2012,19(6):563-571. [35] Chu M C,Zhang X,Gentzschein E,et al.Formation of ethinyl estradiol in women during treatment with norethindrone acetate[J].The Journal of Clinical Endocrinology&Metabolism,2007,92(6):2205-2207. [36] Gu SC,Yang BC.An analysis of the scope of symptoms and treatment of an accumulation of symptoms.JiangSu Journal of Traditional Chinese Medicine.2017;49:11-3. [37] Guo JL.Effects of mifepristone combined with Guizhi Fuling Capsules on treating adenomyosis in 34 cases.Chongqing Medicine.2011;40:673-5. [38] Zhu L,Li D,Ni J,Zhang W,Han H.An analysis of prescriptions for the treatment of women's syndrome in synopsis of golden chamber.Chinese Journal of Information on Traditional Chinese Medicine.2016;23:100-1. [39] Hu NN,Zhao C,Zhang JQ,Wang X,Yang DX,Wu XH.Clinical and mechanism research progress of cassia twigi tuckaing pill in the treatment of endometriosis.Acta Chinese Medicine and Pharmacology.2017;45:104-7. [40] Ortmann O,Weiss J M,Diedrich K.Gonadotrophin-releasing hormone(GnRH)and GnRH agonists:mechanisms of action[J].Reproductive biomedicine online,2002,5:1-7. [41] Khan K N,Fujishita A,Hiraki K,et al.Bacterial contamination hypothesis:a new concept in endometriosis[J].Reproductive medicine and biology,2018,17(2):125-133. [42] Wang Y Q,Zhang S F,Chen X,et al.Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis[J].Zhonghua fu Chan ke za zhi,2009,44(7):504-508. [43] Hurst B S,Gardner S C,Tucker K E,et al.Delayed oral estradiol combined with leuprolide increases endometriosis-related pain[J].JSLS:Journal of the Society of Laparoendoscopic Surgeons,2000,4(2):97. [44] Zupi E,Marconi D,Sbracia M,et al.Add-back therapy in the treatment of endometriosis-associated pain[J].Fertility and sterility,2004,82(5):1303-1308. [45] Fawzy M,Mesbah Y.Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis:a prospective clinical trial[J].Archives of gynecology and obstetrics,2015,292:1267-1271. [46] 赵梦丹,李君琴,杨佩磊,等.不同促性腺激素释放激素激动剂治疗子宫内膜异位症的应用情况和疗效分析[J].中国现代应用药学,2020,37(05):604-607. [47] Li X,Kang X,Deng Q,et al.Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity:a controlled experimental animal study[J].Reproductive Biology and Endocrinology,2013,11:1-8. [48] Li Z,yuan Zhang H,jun Zhu Y,et al.A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women[J].European Journal of Obstetrics&Gynecology and Reproductive Biology,2014,183:164-168. [49] Yang J,Lu Y,Zhang Y,et al.Acupuncture combined with gonadotropin-releasing hormone agonists improves endometrial receptivity and pregnancy outcome in patients with recurrent implantation failure of in vitro fertilization-embryo transfer[J].Journal of Assisted Reproduction and Genetics,2024:1-8. [50] Hao H,Li M,Zhang C,et al.The effect of gonadotropin-releasing hormone agonist downregulation in conjunction with hormone replacement therapy on endometrial preparation in patients for frozen–thawed embryo transfer[J].Frontiers in Medicine,2024,11:1412126. [51] Lamb Y N.Elagolix:first global approval[J].Drugs,2018,78(14):1501-1508. [52] Harada T,Osuga Y,Suzuki Y,et al.Relugolix,an oral gonadotropin-releasing hormone receptor antagonist,reduces endometriosis-Associated pain compared with leuprorelin in Japanese women:a phase 3,randomized,double-blind,noninferiority study[J].Fertility and Sterility,2022,117(3):583-592.

点击下载PDF